Varsha Chandnani
-
Cohance Lifesciences Shares In Focus: Here's Why The Former Cipla Top Boss Is A Strategic Fit
Vohra's track record at Cipla makes him a strategic fit for Cohance, which is itself navigating a similar transition, from volume manufacturing toward value-based partnerships with innovator and specialty pharma clients.
-
IEX Shares Plunge After CERC Draft Rules Proposes Market Coupling
Currently, IEX acts as India's leading platform for spot electricity price discovery.
-
Fertiliser Stocks In Focus: Double Whammy for Indian Firms As China Ban Meets Iran War Disruption
China's move to curb exports of sulphuric acid—particularly the by-product from copper and zinc smelting—signals a shift toward domestic prioritisation ahead of its peak crop planting season.
-
Acutaas Chemicals: The One Stock Winning Bear Market With 'Battery Blood'
Acutaas shares have soared 85% over the last six months. The company is finding massive market success by pivoting to electric vehicle battery solvents.
-
Nifty Q3 Scorecard: SBI, TechM Power Ahead As Reliance, Tata Motors PV Slip
Among the standout performers, State Bank of India led the charts with its highest-ever quarterly profit, buoyed by a sharp rise in non-interest income.
-
Beaten Down, Not Out: Top Five Stocks That Made A December Comeback
These heavy underperformers between January and November posted notable gains in December.
-
Nifty Pharma Underperforms In 2025, Highlighting Stock-Picker's Market
With most big names failing to impress, the year turned into a classic stock-picker’s game, proof that even in a dull market, the right pills can still cure portfolios.
-
Pharma Q2FY26 Preview: Sector Faces a Transition Quarter as gRevlimid Declines and GST Impact Weigh on Growth
Lower US sales of gRevlimid are a major drag for Dr. Reddy’s, Zydus, Aurobindo, and Cipla.
-
Deals, Drugs, And Disruption: Glenmark, Lupin, IPCA Labs And Others Lead India's Pharma Opportunity Boom
The pharmaceutical sector has seen a flurry of new deals, partnerships, and drug launches this week, presenting potential significant growth opportunities in oncology, biosimilars, and diabetes care.
-
Revised US Biosecure Act Could Unlock Opportunities For Indian Pharma Companies
As US drug makers reduce dependence on Chinese players, Indian CDMOs are poised to capture new opportunities.
-
August CPI Review: Analysts See India Inflation Benign, Food Prices Remain Key Swing Factor
Brokerages see the near-term outlook as “benign” but diverge on the policy path, weighing factors like GST cuts, monsoon effects, and imported inflation shocks.
-
Tata Power Q1 Results: Profit Rises 9%, Revenue Up 4%
Tata Power's revenue rose 4% to Rs 18,035 crore in the quarter ended June.
-
Sun Pharmaceutical Q1 Results: Profit Falls 20% As Exceptional Loss Weighs
Sun Pharma's Q1 net profit fell 19% year-on-year to Rs 2,154 crore in the June quarter.
-
NTPC Q1 Results: Profit Rises 6%, Revenue Declines
Margin narrows to 24.2% versus 28% in the year-ago period.
-
Cipla Q1 Results: Net Profit Rises 10% To Rs 1,298 Crore, Beats Estimates
Cipla Q1 Results: Cipla posted a consolidated net profit of Rs 1,298 crore, topping Rs 1,198 crore consensus estimate of analysts tracked by Bloomberg.
